Catalio Capital Management, LP — 13F Holdings & Portfolio
CIK 1958125 · latest 13F-HR filed 2026-08-14
Catalio Capital Management, LP manages $532.1M in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AVLN (10.37%), JNJ (6.63%), GILD (6.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 13; 20 existing positions rose in reported value and 7 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- GILEAD SCIENCES INC$11.2M +48.9%
- SEPTERNA INC$10.9M +153.8%
- NATERA INC$8.1M +57.3%
- HEARTFLOW INC$7.3M +74.2%
- DEFINIUM THERAPEUTICS INC$6.9M +34.9%
Top Trims
- DIANTHUS THERAPEUTICS INC-$43.8M -93.2%
- ULTRAGENYX PHARMACEUTICAL IN-$7.3M -40.8%
- VERADERMICS INC-$5.3M -48.6%
- BRISTOL-MYERS SQUIBB CO-$1.7M -6.7%
- PROTARA THERAPEUTICS INC-$1.0M -34.2%
New Positions
- AVALYN PHARMACEUTICALS INC$55.2M
- JOHNSON & JOHNSON$35.3M
- PARABILIS MEDICINES INC$22.6M
- PROTAGONIST THERAPEUTICS INC$13.1M
- AXSOME THERAPEUTICS INC.$10.6M
Exited Positions
- ASCENDIS PHARMA A/S$29.5M
- TERNS PHARMACEUTICALS INC$21.6M
- SOLENO THERAPEUTICS INC$19.3M
- BOSTON SCIENTIFIC CORP$18.8M
- CYTOKINETICS INC$14.2M
Catalio Capital Management, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $55.2M | 10.37% | 1,675,830 | SH |
| 2 | JOHNSON & JOHNSON | JNJ | 478160104 | $35.3M | 6.63% | 138,946 | SH |
| 3 | GILEAD SCIENCES INC | GILD | 375558103 | $34.0M | 6.39% | 269,309 | SH |
| 4 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $33.9M | 6.37% | 455,041 | SH |
| 5 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $26.6M | 4.99% | 1,215,698 | SH |
| 6 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $26.5M | 4.97% | 562,672 | SH |
| 7 | BRISTOL-MYERS SQUIBB CO | BMY | 110122108 | $23.8M | 4.47% | 412,961 | SH |
| 8 | PARABILIS MEDICINES INC | PBLS | 698955101 | $22.6M | 4.24% | 824,043 | SH |
| 9 | NATERA INC | NTRA | 632307104 | $22.3M | 4.19% | 82,181 | SH |
| 10 | INCYTE CORP | INCY | 45337C102 | $21.7M | 4.08% | 191,627 | SH |
| 11 | SEPTERNA INC | SEPN | 81734D104 | $18.0M | 3.37% | 536,152 | SH |
| 12 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $17.5M | 3.29% | 648,722 | SH |
| 13 | HEARTFLOW INC | HTFL | 42238D107 | $17.1M | 3.21% | 583,055 | SH |
| 14 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $16.1M | 3.03% | 1,080,888 | SH |
| 15 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $14.8M | 2.79% | 276,550 | SH |
| 16 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $13.1M | 2.46% | 106,799 | SH |
| 17 | DISC MEDICINE INC | IRON | 254604101 | $11.7M | 2.19% | 159,384 | SH |
| 18 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $11.3M | 2.12% | 124,778 | SH |
| 19 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $10.6M | 1.99% | 43,182 | SH |
| 20 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $10.6M | 1.98% | 316,252 | SH |
| 21 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $10.3M | 1.94% | 468,750 | SH |
| 22 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $9.2M | 1.73% | 940,855 | SH |
| 23 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $8.6M | 1.61% | 457,839 | SH |
| 24 | ASCENDIS PHARMA A/S | ASND | K08588103 | $8.5M | 1.59% | 31,759 | SH |
| 25 | KARDIGAN INC | KARD | 485925101 | $7.5M | 1.40% | 312,500 | SH |
| 26 | ELEDON PHARMACEUTICALS INC | ELDN | 28617K101 | $6.7M | 1.26% | 1,695,071 | SH |
| 27 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $6.3M | 1.18% | 471,254 | SH |
| 28 | VERADERMICS INC | MANE | 922967104 | $5.6M | 1.06% | 45,856 | SH |
| 29 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $5.4M | 1.02% | 244,929 | SH |
| 30 | FRACTYL HEALTH INC | GUTS | 35168W103 | $4.9M | 0.92% | 6,168,749 | SH |
| 31 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $4.7M | 0.88% | 148,045 | SH |
| 32 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $3.2M | 0.60% | 32,941 | SH |
| 33 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $2.4M | 0.46% | 318,407 | SH |
| 34 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $2.0M | 0.37% | 520,148 | SH |
| 35 | HYPERFINE INC | HYPR | 44916K106 | $1.8M | 0.33% | 1,320,041 | SH |
| 36 | ATAIBECKLEY INC | ATAI | 04650F101 | $1.0M | 0.19% | 196,858 | SH |
| 37 | METAGENOMI THERAPEUTICS INC | MGX | 59102M104 | $629.5K | 0.12% | 528,993 | SH |
| 38 | OUTSET MED INC | OM | 690145206 | $511.0K | 0.10% | 118,279 | SH |
| 39 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $367.9K | 0.07% | 14,718 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $532.1M | 39 | 0001958125-26-000005 |
| 2026-03-31 | 2026-05-15 | $478.7M | 41 | 0001958125-26-000003 |
| 2025-12-31 | 2026-02-17 | $565.8M | 45 | 0001958125-26-000002 |
| 2025-12-31 | 2026-09-02 | $565.8M | 45 | 0001958125-26-000007 |
| 2025-09-30 | 2025-11-14 | $540.9M | 38 | 0001958125-25-000009 |
5TH FLOOR
NEW YORK, NY 10011